A Phase 1 study of CBT-501 in south-east Asia.
Latest Information Update: 02 Sep 2016
At a glance
- Drugs APL-102 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 02 Sep 2016 New trial record
- 29 Aug 2016 According to CBT Pharmaceuticals media release, company is planning to start this trial in 2017.